Print this page

AP & T 15 May 2017

AP&T: CONTENTS LISTING FOR THE 15th MAY 2017 ISSUE

The contents listing for the 15th May 2017 issue of Alimentary Pharmacology & Therapeutics is listed below and, as a member of the New Zealand Society of Gastroenterology, you have free access to all these articles when you log-in via the Members’ Area of the NZSG website - www.nzsg.org.nz

Yours sincerely

Roy

Professor R E Pounder
Co-Editor
Alimentary Pharmacology & Therapeutics
website: www.APandT.org
Follow AP&T on Twitter: @APandT

------------------------------------------------------------------------------------------------------

CONTENTS LIST FOR 15th MAY 2017 ISSUE OF
ALIMENTARY PHARMACOLOGY & THERAPEUTICS



SYSTEMATIC REVIEWS WITH META-ANALYSES

Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials (pages 1291–1302)
A. Cholapranee, G. S Hazlewood, G. G. Kaplan, L. Peyrin-Biroulet and A. N. Ananthakrishnan

Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease (pages 1303–1318)
A. Aksan, H. Işık, H. H. Radeke, A. Dignass and J. Stein


ELUXADOLINE FOR IRRITABLE BOWEL SYNDROME


Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies (pages 1319–1328)
W. D. Chey, L. S. Dove, D. A. Andrae and P. S. Covington


PREGNANCY AND PHARMACOKINETICS OF ANTI-TNFs

The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease (pages 1329–1338)
C. H. Seow, Y. Leung, N. Vande Casteele, E. Ehteshami Afshar, D. Tanyingoh, G. Bindra, M. J. Stewart, P. L. Beck, G. G. Kaplan, S. Ghosh and R. Panaccione


OESOPHAGEAL HISTOLOGY IN GERD

The dynamics of the oesophageal squamous epithelium ‘normalisation’ process in patients with gastro-oesophageal reflux disease treated with long-term acid suppression or anti-reflux surgery (pages 1339–1349)
L. Mastracci, R. Fiocca, C. Engström, S. Attwood, C. Ell, J. P. Galmiche, J. G. Hatlebakk, G. Långström, S. Eklund, T. Lind and L. Lundell

Diagnosis of gastro-oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain (pages 1350–1357)
N. Vakil, M. Vieth, B. Wernersson, J. Wissmar and J. Dent


FUNCTIONAL DYSPEPSIA AND DUODENAL EOSINOPHILIA

Functional dyspepsia is associated with duodenal eosinophilia in an Australian paediatric cohort (pages 1358–1364)
L. Wauters, S. Nightingale, N. J. Talley, B. Sulaiman and M. M. Walker


INVITED EDITORIALS


Editorial: clinical benefits of vitamin D therapy in inflammatory bowel disease (pages 1365–1366)

A. B. Hawthorne

Editorial: inflammatory bowel disease risk reduction after migration – are early life events important? (pages 1367–1368)
M. J. Lamba, V. S. Tharayil and R. B. Gearry

Editorial: Clostridium difficile and inflammatory bowel disease – is it always a bad combination? (pages 1368–1369)
A. Nelson and H. H. Tsai

Editorial: importance of definition of inflammatory bowel disease and an increased incidence in children (pages 1369–1370)
Å. H. Everhov, O. Olén and J. F. Ludvigsson

Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases (pages 1370–1371)
R. Felwick and J. R. F. Cummings

Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases – authors’ reply (page 1372)
Y. Komaki, A. Yamada, F. Komaki, D. Micic, A. Ido and A. Sakuraba

Editorial: hepatitis B reactivation in patients with chronic hepatitis C treated with direct-acting antivirals – incidence, severity of hepatitis and lessons to learn (pages 1373–1374)
C.-H. Chen

Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience (pages 1374–1375)
S. Khorrami and J. P. Gisbert


LETTER TO THE EDITORS

Letter: chronic hepatitis C genotype 3 infection – still a hurdle toward a direct-acting anti-viral-induced HCV cure? (pages 1376–1377)
G. Bruno, M. Milella, G. Angarano and A. Saracino

 


Previous page: NZSG Secretariat
Next page: AP & T 1 June 2017